This site is for healthcare professionals only. If you are not a healthcare professional please click here

Prescribing information and adverse event reporting information can be found at the bottom of this webpage.

Astellas GU Masterclass: XTANDI™(enzalutamide)

Day 2 | Saturday 5 July 2025, 8:30–14:30 CEST

Day 2 – Prostate Cancer

Plenary slides

Session 1 – Impactful data in mHSPC over the
last year

Stéphane Oudard, Oncologist, France 
Antonio Alcaraz, Urologist, Spain 
Ugo de Giorgi, Oncologist, Italy 
40 minutes

A summary of important recent data that is likely to impact prostate cancer care

Download

Session 2 – The importance of first
treatment choice

Arnulf Stenzl, Urologist, Germany 
25 minutes

An exploration of the key impact of first treatment and the importance of making the right choice

Download

Session 3 – The EMBARK trial in clinical practice

Derya Tilki, Urologist, Germany 
Thomas Zilli, Radiation Oncologist, Switzerland 
Thomas Steuber, Urologist, Germany 
40 minutes

Real-world experiences of managing patients with nmHSPC with high-risk biochemical recurrence

Download

Session 4 – The value of molecular imaging and its impact on treatment choices

Bertrand Tombal, Oncologist, Belgium 
Fabio Calabrò, Oncologist, Italy 
40 minutes

An overview of how molecular imaging might inform treatment decisions in prostate cancer, including an illustrative case study

Download

Session 5 – Faculty debate: Treatment choice today for patients with mHSPC

Shahrokh Shariat, Urologist, Austria 
Vincent Khoo, Oncologist, UK 
30 minutes

A discussion of the key factors impacting treatment decision-making for patients with mHSPC

Download

Session 6 (Workshops): Care for patients with advanced prostate cancer: Adding life to years – Fatigue

Antonio Alcaraz, Urologist, Spain 
Stéphane Oudard, Oncologist, France 
20 minutes

A case study-based workshop exploring options for management of fatigue in patients with advanced prostate cancer

Download

Session 6 (Workshops): Care for patients with advanced prostate cancer: Adding life to years – Bone health

Ugo de Giorgi, Oncologist, Italy 
Vincent Khoo, Oncologist, UK 
20 minutes

A case study-based workshop highlighting the importance of bone health management in patients with advanced prostate cancer

Download

Session 6 (Workshops): Care for patients with advanced prostate cancer: Adding life to years – DDIs

Romano Danesi, Pharmacologist, Italy 
Fabio Calabrò, Oncologist, Italy 
20 minutes

A case study-based workshop exploring the clinical relevance of DDIs in patients treated for advanced prostate cancer

Download

Session 7 – Advances in AI in advanced
prostate cancer

Antonio Alcaraz, Urologist, Spain 
30 minutes

An overview of recent and potential advances in using AI in caring for patients with prostate cancer

Download

Prescribing Information

UK Prescribing Information is available for XTANDI™(enzalutamide) here. Dutch Prescribing Information for XTANDI™(enzalutamide) is available here.

XTANDI is indicated:

As monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high-risk biochemical recurrent nmHSPC who are unsuitable for salvage-radiotherapy
In combination with androgen deprivation therapy for the treatment of adult men with mHSPC
For the treatment of adult men with high-risk non-metastatic CRPC
For the treatment of adult men with metastatic CRPC who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated
For the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy

AE reporting information

NL: Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Nederland: Nederlands Bijwerkingen Centrum Lareb;
Website: www.lareb.nl

UK: Adverse events should be reported.

Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for ‘MHRA yellow card’ in the Google Play Store or Apple App Store. Adverse events should also be reported to Astellas Pharma Ltd on 0800 783 5018

XTANDI is approved for use in multiple indications for the treatment of adult patients with advanced prostate cancer. Please refer to the specific marketing status for your country/market.

AE, adverse event; AI, artificial intelligence; CRPC, castration-resistant prostate cancer; DDI, drug-drug interaction; mHSPC, metastatic hormone-sensitive prostate cancer; nmHSPC, non-metastatic hormone-sensitive prostate cancer